Series Of Individually Immaterial Business Acquisitions
Share price: $9.20
FACT II ACQUISITION CORP. — Key Metrics
1 years of history · ending 2025-12-31 · SEC EDGAR
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
Return on Equity
-58.9%
Return on Assets
2.7%
Return on Invested Capital
20.6%
Current Ratio
27.11
Quick Ratio
27.11
Asset Turnover
0.00
Working Capital
$614K
Net Current Asset Value
$-9M
Invested Capital
$-9M
OCF / Net Income
-0.18
FCF / Net Income
-0.18
Accruals Ratio (Sloan)
3.2%
Tangible Common Equity
$-9M
TCE / Total Assets
-4.6%
NOPAT
$-2M
Cash ROIC
10.6%
WC / Revenue
2206.3%
Stock Price (FY-end)
$10
Beta (5Y)
0.01
Cost of Equity
4.5%
52W High
$10
52W Low
$10
Trailing Return 1Y
5.4%
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Stock Price on Earnings Dates
FACT II ACQUISITION CORP. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.